| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/29/2003 | EP0817772B1 Pyrrolidinyl hydroxamic acid compounds and their production process |
| 01/29/2003 | EP0572560B1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 01/29/2003 | EP0546007B2 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients |
| 01/29/2003 | CN1394205A Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1394199A Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof |
| 01/29/2003 | CN1394142A Use of cyclic ether for preparation of medicaments affecting glucose tolerance |
| 01/29/2003 | CN1394140A Prostaglandin compositions and method of treatment for male erectile dysfunction |
| 01/29/2003 | CN1394138A Hair growth stimulant |
| 01/29/2003 | CN1393444A Compound for treating impotence |
| 01/29/2003 | CN1393238A Longli hernia pill (powder) and its preparing process |
| 01/29/2003 | CN1393231A Antisanility health-care cream and its preparing process |
| 01/29/2003 | CN1393223A Application of Na-ion channel blocker and aspirin in preparing antalgic medicine for mammal |
| 01/29/2003 | CN1100057C Chromene compounds, process for their preparation and pharmaceutical compositions containing them |
| 01/29/2003 | CN1100055C Piperazine and piperidine compounds |
| 01/29/2003 | CN1100046C 喹唑啉衍生物 Quinazoline derivatives |
| 01/29/2003 | CN1099879C Tonic wine capable of promoting blood circulation |
| 01/29/2003 | CA2417631A1 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/28/2003 | WO2002018372A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 01/28/2003 | WO2002009757A1 Preventives or remedies for obesity or fatty liver |
| 01/28/2003 | US6512123 Antiproliferative agents |
| 01/28/2003 | US6512112 Useful as prodrugs, easily convert to parent amine in vivo; antibiotic activity versus gram negative aerobic and anaerobic bacteria |
| 01/28/2003 | US6512099 Roselipin derivative |
| 01/28/2003 | US6512004 Promoters of neural regeneration |
| 01/28/2003 | US6512001 D-proline derivatives |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511995 Inhibits collagen synthesis, which is useful for prophylaxis or treatment of fibrosis |
| 01/28/2003 | US6511991 Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
| 01/28/2003 | US6511990 Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| 01/28/2003 | US6511989 For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death |
| 01/28/2003 | US6511987 Heterocyclic derivatives that bind to the benzodiazepine site of GABAA receptors for treatment of central nervous system disorders |
| 01/28/2003 | US6511986 Method of treating estrogen receptor positive carcinoma |
| 01/28/2003 | US6511980 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder |
| 01/28/2003 | US6511979 Methods for treating conditions modulated by lactosylceramide |
| 01/28/2003 | US6511978 Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations |
| 01/28/2003 | US6511973 Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses |
| 01/28/2003 | US6511966 Administering for therapy of mitochondria medited disease |
| 01/28/2003 | US6511963 Treating excitotoxicity resulting from over- stimulation of the NMDA receptor which comprises administering agent selected from the group consisting of Conantokin-G, a Conantokin-G derivative and salts thereof |
| 01/28/2003 | US6511847 Recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect in the transfected cells; tumor suppressor gene |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511813 Identifying compound which inhibits peptide bond reaction of a complex formed by interaction of EFP, N-formyl methionyl-tRNA, 30S subunit, 50S subunit, an mRNA containing AUG sequence, initiation factors 1, 2, 3, and peptide bond donor |
| 01/28/2003 | US6511811 Protein kinase C antagonist related to insulin receptor |
| 01/28/2003 | US6511684 Cosmetics or dermitologicals from such as inga bourgoni, goupia glabra or eperua falcate for skin, mucous membranes and/or epithelium |
| 01/28/2003 | US6511683 Enchinacea supplement and method of manufacture |
| 01/28/2003 | US6511662 Treatment of cytomegalovirus using aminopeptidase N |
| 01/28/2003 | CA2417492A1 Preventives or remedies for obesity or fatty liver |
| 01/28/2003 | CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/28/2003 | CA2307101C Pharmaceutical articles of manufacture comprising selective phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| 01/28/2003 | CA2284910C Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 01/28/2003 | CA2245269C Solid pharmaceutical dispersions with enhanced bioavailability |
| 01/28/2003 | CA2148839C Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 01/28/2003 | CA2124375C Compounds containing a fused bicyclic ring and processes therefor |
| 01/28/2003 | CA2108369C Method and composition for ameliorating the adverse effects of aging |
| 01/28/2003 | CA2033469C Composition and method for the treatment of osteoporosis in mammals |
| 01/27/2003 | WO2002010127A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | WO2002007713A2 Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| 01/27/2003 | CA2417677A1 Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| 01/27/2003 | CA2417427A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006628A2 Nad synthetase inhibitors and uses thereof |
| 01/23/2003 | WO2003006612A2 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006607A2 Inhibition of apoptosis process and improvement of cell performance |
| 01/23/2003 | WO2003006604A2 Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006490A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | WO2003006471A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | WO2003006466A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | WO2003006460A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006452A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 01/23/2003 | WO2003006447A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | WO2003006441A1 Crystalline thiazine oxazolidinones |
| 01/23/2003 | WO2003006440A2 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | WO2003006436A1 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 01/23/2003 | WO2003006430A1 Taxol enhancer compounds |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006423A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 01/23/2003 | WO2003006060A1 Sh3 domain binding inhibitors |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006052A1 Sustained-release compositions for injection and process for producing the same |
| 01/23/2003 | WO2003006050A1 Preventives/remedies for brain edema |
| 01/23/2003 | WO2003006041A1 Preventives/remedies for malignant tumor |
| 01/23/2003 | WO2003006037A1 Remedies |
| 01/23/2003 | WO2003006031A1 Calcium salts with cytotoxic activity |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006024A1 Medicine containing pyrimidine derivative |
| 01/23/2003 | WO2003006021A1 Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003006013A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006002A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005956A2 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | WO2003005955A2 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |